Patents by Inventor D. Davidson Easson, Jr.
D. Davidson Easson, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100047292Abstract: A method for processing multi-phasic dispersions is provided. The method comprises providing a multi-phasic dispersion including dispersed and continuous phases, positioning the multi-phasic dispersion within a chamber capable of being pressurized, pressurizing the chamber with a first gas to a pressure less than the supercritical pressure of the gas, and contacting the multi-phasic dispersion with the first gas.Type: ApplicationFiled: August 20, 2008Publication date: February 25, 2010Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Mei Tsung, D. Davidson Easson, JR., Eugene Mehr, Alain L. Bourhis
-
Patent number: 7566704Abstract: The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble ?-glucan composition comprising ?-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).Type: GrantFiled: January 17, 2006Date of Patent: July 28, 2009Assignee: Biopolymer Engineering, Inc.Inventors: Myra L. Patchen, Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 7022685Abstract: The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble ?-glucan composition comprising ?-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).Type: GrantFiled: March 7, 2002Date of Patent: April 4, 2006Assignee: Biopolymer Engineering, Inc.Inventors: Myra L. Patchen, Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 6369216Abstract: The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble &bgr;-glucan composition comprising &bgr;-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).Type: GrantFiled: June 3, 1999Date of Patent: April 9, 2002Assignee: Biopolymer Engineering Pharmaceutical, Inc.Inventors: Myra L. Patchen, Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 6143731Abstract: Compositions useful in the treatment of dietary disorders, and as dietary additives to provide a source of fiber and of short chain fatty acids, to reduce the level of serum cholesterol, increase HDL cholesterol levels and as bulking agents in humans and animals, as well as methods of use therefor are described. The compositions and methods are based on whole .beta.-glucans.Type: GrantFiled: July 27, 1999Date of Patent: November 7, 2000Assignee: The Collaborative Group, Ltd.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Bruce R. Bistrian
-
Patent number: 6020324Abstract: Compositions useful in the treatment of dietary disorders, and as dietary additives to provide a source of fiber and of short chain fatty acids, to reduce the level of serum cholesterol and as bulking agents in humans and animals, as well as methods of use therefor are described. The compositions and methods are based on whole .beta.-glucans.Type: GrantFiled: April 26, 1991Date of Patent: February 1, 2000Assignee: The Collaborative Group, Ltd.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Bruce R. Bistrian
-
Patent number: 5849720Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.Type: GrantFiled: March 8, 1995Date of Patent: December 15, 1998Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5817643Abstract: The present invention relates to neutral, aqueous soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble .beta.-glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble .beta.-glucan of this invention neither induces nor primes IL-1.beta. and TNF.alpha. production in vitro and in vivo. Safe and efficacious preparations of neutral, aqueous soluble .beta.Type: GrantFiled: June 6, 1995Date of Patent: October 6, 1998Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5811542Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.Type: GrantFiled: May 2, 1995Date of Patent: September 22, 1998Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5783569Abstract: The present invention relates to neutral, aqueous soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble .beta.-glucan preparation has a high affinity for the .beta.-glucans receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble .beta.-glucans of this invention neither induces nor primes IL-1.beta. and TNF.alpha. production in vitro and in vivo. Safe and efficacious preparations of neutral, aqueous soluble .beta.Type: GrantFiled: January 26, 1995Date of Patent: July 21, 1998Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5741495Abstract: The invention describes a whole .beta.-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use. A drug is incorporated into a whole .beta.-glucan microparticle, and the combination is administered to an individual. The .beta.-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.Type: GrantFiled: February 27, 1997Date of Patent: April 21, 1998Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, Gary R. Ostroff, D. Davidson Easson, Jr.
-
Patent number: 5663324Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.Type: GrantFiled: June 5, 1995Date of Patent: September 2, 1997Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros James, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5633369Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.Type: GrantFiled: June 5, 1995Date of Patent: May 27, 1997Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5622939Abstract: The present invention relates to neutral soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo. Safe and efficacious preparations of neutral soluble glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g.Type: GrantFiled: August 21, 1992Date of Patent: April 22, 1997Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5607677Abstract: The invention describes a whole .beta.-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use. A drug is incorporated into a whole .beta.-glucan microparticle, and the combination is administered to an individual. The .beta.-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.Type: GrantFiled: December 13, 1991Date of Patent: March 4, 1997Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, Gary R. Ostroff, D. Davidson Easson, Jr.
-
Patent number: 5532223Abstract: The present invention relates to neutral soluble .beta.-glucans which exert potent and specific hematopoietic and immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo.Type: GrantFiled: May 30, 1995Date of Patent: July 2, 1996Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5504079Abstract: Modified yeast cell wall glucans are administered to patients who are at risk for infection due to imminent surgery, chemotherapy or other treatment which affects the immune system, in order to mobilize the cellular defense mechanisms and boost the immune response of the patient before, during and after the surgery, chemotherapy or other treatment.Type: GrantFiled: November 14, 1994Date of Patent: April 2, 1996Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5488040Abstract: The present invention relates to neutral soluble .beta.-glucans which exert potent and specific hematopoietic and immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human mono-cytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo.Type: GrantFiled: May 11, 1993Date of Patent: January 30, 1996Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5322841Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence or acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.Type: GrantFiled: November 2, 1992Date of Patent: June 21, 1994Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5032401Abstract: The invention describes a whole .beta.-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use. A drug is incorporated into a whole .beta.-glucan microparticle, and the combination is administered to an individual. The .beta.-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.Type: GrantFiled: June 15, 1989Date of Patent: July 16, 1991Assignee: Alpha Beta TechnologyInventors: Spiros Jamas, Gary R. Ostroff, D. Davidson Easson, Jr.